NASDAQ:HLVX HilleVax - HLVX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.29 -0.07 (-0.46%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.00▼$15.4450-Day Range$15.00▼$18.1852-Week Range$7.90▼$24.42Volume29,649 shsAverage Volume44,979 shsMarket Capitalization$600.13 millionP/E RatioN/ADividend YieldN/APrice Target$32.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media HilleVax MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside109.3% Upside$32.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment1.13Based on 12 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.96) to ($3.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector339th out of 1,005 stocksBiological Products, Except Diagnostic Industry58th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingHilleVax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, HilleVax has a forecasted upside of 109.3% from its current price of $15.29.Amount of Analyst CoverageHilleVax has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HLVX. Previous Next 0.0 Dividend Strength Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLVX. Previous Next 2.9 News and Social Media Coverage News SentimentHilleVax has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for HilleVax this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have not sold or bought any company stock.Percentage Held by Insiders29.70% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.11% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for HilleVax are expected to grow in the coming year, from ($3.96) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About HilleVax (NASDAQ:HLVX) StockHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Read More Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address HLVX Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comQ1 2023 Earnings Estimate for HilleVax, Inc. (NASDAQ:HLVX) Issued By SVB LeerinkMarch 22, 2023 | americanbankingnews.comHilleVax, Inc. (NASDAQ:HLVX) to Post Q1 2024 Earnings of ($0.91) Per Share, SVB Leerink ForecastsMarch 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 20, 2023 | finanznachrichten.deHilleVax, Inc.: HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company ProgressMarch 17, 2023 | finance.yahoo.comHilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company ProgressMarch 17, 2023 | americanbankingnews.comHilleVax (NASDAQ:HLVX) Shares Down 10.3% March 16, 2023 | americanbankingnews.comHilleVax (NASDAQ:HLVX) vs. Elevation Oncology (NASDAQ:ELEV) Critical ContrastJanuary 9, 2023 | finance.yahoo.comHilleVax Announces Executive Management Appointments and PromotionsMarch 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. January 4, 2023 | finance.yahoo.comHilleVax to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 30, 2022 | bizjournals.comHilleVax, Boston’s biggest IPO of 2022, wants to end common norovirus effectDecember 14, 2022 | finance.yahoo.comAfter Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)December 13, 2022 | finance.yahoo.comDown 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)December 7, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on HilleVax, Inc (HLVX)December 5, 2022 | markets.businessinsider.comHilleVax Reports Positive Immunogenicity Results For Phase 2b Trial For HIL-214December 5, 2022 | finance.yahoo.comHilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine CandidateNovember 18, 2022 | finance.yahoo.comHere's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)November 15, 2022 | finance.yahoo.comWall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should KnowNovember 14, 2022 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on HilleVax, Inc (HLVX)November 11, 2022 | finanznachrichten.deHilleVax, Inc.: HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNovember 10, 2022 | finance.yahoo.comHilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressNovember 10, 2022 | finance.yahoo.comHilleVax to Participate in November Investor ConferencesSeptember 2, 2022 | barrons.comHilleVax Inc.September 1, 2022 | tmcnet.comHilleVax to Participate in J.P. Morgan Biotech - 2022 Conference Call SeriesSeptember 1, 2022 | finance.yahoo.comHilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call SeriesAugust 31, 2022 | finance.yahoo.comHilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine CandidateAugust 15, 2022 | finance.yahoo.comHilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine ForumSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address HLVX Company Calendar Today3/25/2023Next Earnings (Estimated)6/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HLVX CUSIPN/A CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+109.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($13.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-159,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.75% Return on Assets-58.37% Debt Debt-to-Equity Ratio0.06 Current Ratio22.28 Quick Ratio34.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares39,250,000Free Float27,594,000Market Cap$600.13 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Robert M. Hershberg M.D. (Age 61)Ph.D., Pres, CEO & Chairman Comp: $611.2kMr. David A. Socks (Age 48)CFO & Chief Bus. Officer Comp: $561.72kMr. Aditya Kohli Ph.D. (Age 35)COO & Director Comp: $576.55kDr. Anju Chatterji Ph.D.Sr. VP of Technical OperationsMr. Paul S. Bavier J.D. (Age 51)Gen. Counsel, Sec. & Chief Admin. Officer Ms. Astrid Borkowski M.D. (Age 53)Ph.D., Chief Medical Officer Ms. Kaia AgarwalSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATEJATT AcquisitionNYSE:JATTEditas MedicineNASDAQ:EDITNovavaxNASDAQ:NVAXImmaticsNASDAQ:IMTXView All CompetitorsInstitutional OwnershipT. Rowe Price Investment Management Inc.Bought 111,322 shares on 2/15/2023Ownership: 3.632%Alps Advisors Inc.Bought 4,317 shares on 2/15/2023Ownership: 0.068%State of Wisconsin Investment BoardBought 11,760 shares on 2/15/2023Ownership: 0.035%Sandia Investment Management LPSold 1,900 shares on 2/15/2023Ownership: 0.018%Legal & General Group PlcBought 3,466 shares on 2/15/2023Ownership: 0.014%View All Institutional Transactions HLVX Stock - Frequently Asked Questions Should I buy or sell HilleVax stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HLVX shares. View HLVX analyst ratings or view top-rated stocks. What is HilleVax's stock price forecast for 2023? 4 Wall Street research analysts have issued 1 year price targets for HilleVax's shares. Their HLVX share price forecasts range from $24.00 to $40.00. On average, they predict the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 109.3% from the stock's current price. View analysts price targets for HLVX or view top-rated stocks among Wall Street analysts. How have HLVX shares performed in 2023? HilleVax's stock was trading at $16.73 at the beginning of 2023. Since then, HLVX stock has decreased by 8.6% and is now trading at $15.29. View the best growth stocks for 2023 here. When is HilleVax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 14th 2023. View our HLVX earnings forecast. What ETFs hold HilleVax's stock? ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). When did HilleVax IPO? (HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at $16.00-$18.00 per share. What is HilleVax's stock symbol? HilleVax trades on the NASDAQ under the ticker symbol "HLVX." Who are HilleVax's major shareholders? HilleVax's stock is owned by a number of retail and institutional investors. Top institutional investors include Braidwell LP (4.86%), Franklin Resources Inc. (3.74%), T. Rowe Price Investment Management Inc. (3.63%), Morgan Stanley (1.82%), Geode Capital Management LLC (0.83%) and Charles Schwab Investment Management Inc. (0.31%). How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is HilleVax's stock price today? One share of HLVX stock can currently be purchased for approximately $15.29. How much money does HilleVax make? HilleVax (NASDAQ:HLVX) has a market capitalization of $600.13 million. The company earns $-159,810,000.00 in net income (profit) each year or ($13.10) on an earnings per share basis. How can I contact HilleVax? The official website for the company is www.hillevax.com. The company can be reached via phone at 617-213-5054 or via email at ir@hillevax.com. This page (NASDAQ:HLVX) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.